.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,384,020

« Back to Dashboard

Claims for Patent: 6,384,020

Title: Rapid immediate release oral dosage form
Abstract:A pharmaceutical composition comprising lactitol and one or more amphetamine salts in a rapid release formulation.
Inventor(s): Flanner; Henry H. (Montgomery Village, MD), Chang; Rong-Kun (Rockville, MD), Pinkett; Jill E. (Baltimore, MD), Wassink; Sandra E. (Frederick, MD), White; Lisa R. (Damascus, MD)
Assignee: Shire Laboratories, Inc. (Rockville, MD)
Application Number:09/611,098
Patent Claims: 1. A pharmaceutical composition comprising a tablet, said tablet including (i) a pharmaceutical active selected from the group consisting of amphetamine base, salts, chemical and chiral derivatives thereof, and mixtures thereof; (ii) lactitol; and (iii) micro crystalline cellulose.

2. The composition of claim 1 wherein said pharmaceutical active comprises a mixture of amphetamine salts.

3. The composition of claim 2 wherein said amphetamine salts are selected from the group consisting of d-amphetamine sulfate, d,l-amphetamine aspartate, d-amphetamine saccharate, and d,l-amphetamine sulfate.

4. The composition of claim 3 wherein said d-amphetamine sulfate, d,l-amphetamine aspartate, d-amphetamine saccharate, and d,l-amphetamine sulfate are present in said composition in a ratio of 1:1:1:1.

5. The composition of claim 1 wherein said lactitol and said microcrystalline cellulose are present in said composition at a ratio of lactitol to microcrystalline cellulose of 2-5:0.25-1.75.

6. The composition of claim 5 wherein said lactitol and said microcrystalline cellulose are present in said composition at a ratio of lactitol to microcrystalline cellulose of 3-4: 0.5-1.5.

7. The composition of claim 1 and further comprising an antiadherant or glidant.

8. The composition of claim 7 wherein said antiadherant or glidant is selected from the group consisting of talc, corn starch, silicon dioxide, sodium lauryl sulfate, and metallic stearates.

9. The composition of claim 1 and further comprising a lubricant.

10. The composition of claim 9 wherein said lubricant is selected from the group consisting of magnesium stearate, calcium stearate, sodium stearate, stearic acid, sodium stearyl fumarate, sterotex, talc, colloidal silicon dioxide, and waxes.

11. The composition of claim 1 and further comprising a binding agent.

12. The composition of claim 11 wherein said binding agent is selected from the group consisting of polyvinyl pyrrolidone, starch, methyl cellulose, hydroxypropyl methylcellulose, and carboxymethyl cellulose.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc